Bradley Maron is a Cardiology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
Sponsor: Brigham and Women's Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Actelion Pharmaceuticals US, Inc.Program year20251 payment
- Merck Sharp & Dohme LLCProgram year20251 payment
- Regeneron Pharmaceuticals, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
87.5%ACE inhibitor26.9%Lisinopril100%Part D<11 patientsStatin23.1%Atorvastatin Calcium100%Part D<11 patients+ 2 more classes in this area
Blood & clotting
12.5%Factor Xa inhibitor12.5%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
6 NIH research awards on record, funded 2013–2023 per NIH RePORTER. The latest:
- Targeting FAK-NEDD9 protein-protein interaction to prevent focal adhesion assembly and vascular proliferation in pulmonary arterial hypertension
Brigham and Women'S Hospital
FY2023$636,832R01HL139613 - Personalized protein-protein interactomes and precision medicine in pulmonary arterial hypertension
Brigham and Women'S Hospital
FY2023$286,679R01HL155096 - NEDD9-SMAD3, fibrinolysis, and chronic thromboembolic pulmonary hypertension
Brigham and Women'S Hospital
FY2022$432,332R01HL153502
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Martin Leon, MD
Columbia University Irving Medical Center
Scott Solomon, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”